Vantis Vascular has completed the first commercial application of its CrossFAST Integrated Microcatheter Advanced Delivery System.
The procedures were carried out during a series of complex high-risk coronary interventions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The initial clinical use of the system is said to have resulted in a 100% procedural success rate, showing a ‘rapid’ delivery to the target area, and delivery of the stent, with no complications related to the device, the company noted.
Dr Amir Kaki at St John’s Hospital in Detroit, Michigan, US, performed the first procedure using the CrossFAST System.
The system claimed to have shown ‘superior’ deliverability during several complex cases, in contrast with the traditional guide extension catheters, which were not successful in reaching the target lesion.
Designed specifically for complex coronary and peripheral interventions, the system incorporates an integrated microcatheter with a seamless transition, minimising the vessel trauma risk and damage to the stents that are previously placed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe CrossFAST Advanced Delivery System employs DuoPRO Interlocking Technology, which enhances ‘pushability’ and navigation to overcome limitations faced by guide extension catheters.
Vantis Vascular chief clinical officer Frank Saltiel said: “The device’s ability to navigate complex coronary anatomy with ease has the potential to revolutionise the way we approach CHiP procedures.
“We are confident that CrossFAST will play a crucial role in advancing coronary therapy by decreasing procedure times and reducing complications in patients with complex, difficult-to-treat lesions.”
The system is currently available in the US through a limited market release with a full market release anticipated later this year.
Alongside the CrossFAST System, the company is also developing the CrossSHOCK Intravascular Lithotripsy System.
Last May, the company secured $5m in funding through a Simple Agreement for Future Equity financing round to develop its intervention technologies.
